Walters Group insider trades: Zentalis Pharmaceuticals (ZNTL) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Walters Group reports to the SEC
Open-market buys and sales
2 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Aug 14, 2026 | ZNTL | ↑ Buy | 4,335,000 | $3.50 | $15.2M | Direct | Aug 19, 2026 (5d) |
| Dec 31, 2025 | ZNTL | ↑ Buy | 6,459,973 | $1.20 | $7.8M | Direct | Jan 8, 2026 (8d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other ZNTL insiders
Open-market trades in the last 12 months
About Walters Group's insider trades
Walters Group is a 10% owner of Zentalis Pharmaceuticals (ZNTL). Since Dec 31, 2025, it has reported 2 open-market purchases worth $22.9M and no sales on SEC Form 4. In the last 12 months: 2 buys ($22.9M).
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ZNTL insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.